Pannexin 2 (PANX2) (PANX2)

Pannexin 2 (PANX2) is a large-pore transmembrane protein predominantly expressed in the central nervous system, where it forms hemichannels that facilitate the exchange of ions and small signaling molecules like ATP between the intracellular and extracellular environments [1, 3]. Unlike connexins, PANX2 does not typically form gap junctions, but its unique expression pattern in the brain suggests specialized roles in neuronal differentiation and cellular homeostasis [1, 4]. In the context of disease, PANX2 is significantly involved in the progression of glioblastoma, where its expression levels correlate with tumor grade and patient prognosis, making it a potential biomarker and therapeutic target [2, 4]. Additionally, PANX2 has been implicated in the pathophysiology of ischemic stroke and neurodegenerative conditions, where its activation may contribute to secondary cell death [3]. Therapeutic interventions targeting PANX2 include small-molecule inhibitors such as probenecid and carbenoxolone, as well as experimental RNA-based therapies like antisense oligonucleotides designed to degrade PANX2 mRNA [2, 3]. However, achieving isoform specificity remains a challenge, as many current inhibitors also affect PANX1 and other channel proteins [1, 2].

Other names

PX2Pannexin-2hPANX2

Inhibition of hemichannel-mediated ATP release and ion flux; mRNA degradation via antisense oligonucleotides or RNA interference.